Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Leaky Scanning02:28

Leaky Scanning

5.8K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.8K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.2K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.2K
Nucleic Acid Structure01:25

Nucleic Acid Structure

9.6K
The pentose sugar in DNA is deoxyribose, while in RNA the pentose sugar is ribose. The difference between the sugars is the presence of the hydroxyl group on the ribose's second carbon and a hydrogen on the deoxyribose's second carbon. The phosphate residue attaches to the hydroxyl group of the 5′ carbon of one sugar and the hydroxyl group of the 3′ carbon of the sugar of the next nucleotide, which forms  a 5′ to 3′ phosphodiester linkage.
DNA Structure
DNA...
9.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
Initiation of Translation02:33

Initiation of Translation

39.6K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
39.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary mRNA-LNP vaccines for rapid and durable protection against bacterial infection.

Nature communications·2026
Same author

Hydroxyl-Terminated Polyethylene Glycol Evades Human Pre-existing Anti-polyethylene Glycol Antibodies.

ACS nano·2026
Same author

Polyketal-conjugated tafluprost microparticles enable long-acting glaucoma therapy.

Nature communications·2026
Same author

Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma.

Cell research·2025
Same author

Deep generative optimization of mRNA codon sequences for enhanced mRNA translation and therapeutic efficacy.

Nature communications·2025
Same author

A Dual-Specificity d-Peptide Antagonist of MDM2 and MDMX for Antitumor Immunotherapy.

Journal of medicinal chemistry·2025

Related Experiment Video

Updated: Feb 24, 2026

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
08:55

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

14.2K

From Vaccines to Therapeutics: The Need for Distinct mRNA-LNP Design Principles.

Xiaoli Wei1, Changyou Zhan1

  • 1Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, P. R. China.

Journal of Medicinal Chemistry
|February 23, 2026
PubMed
Summary

Therapeutic messenger RNA lipid nanoparticles (mRNA-LNPs) need different designs than vaccines. Strategies like optimizing lipids and molecular design improve safety and efficacy for repeated therapeutic use.

More Related Videos

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

5.1K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K

Related Experiment Videos

Last Updated: Feb 24, 2026

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
08:55

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

14.2K
Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

5.1K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K

Area of Science:

  • Biotechnology
  • Pharmaceutical Sciences
  • Drug Delivery Systems

Background:

  • Messenger RNA (mRNA) therapeutics hold promise but face delivery challenges.
  • Current lipid nanoparticle (LNP) designs are largely optimized for vaccines.
  • Therapeutic applications require enhanced safety and repeated-dose efficacy profiles.

Purpose of the Study:

  • To outline distinct design principles for therapeutic mRNA-LNPs.
  • To identify strategies for improving immune compatibility and safety.
  • To enhance the efficacy of mRNA-LNPs for repeated administration.

Main Methods:

  • Focus on optimizing ionizable lipids for better performance.
  • Investigate modifications or replacements for polyethylene glycol (PEG)-lipids.
  • Employ rational molecular design approaches for LNP formulation.

Main Results:

  • Optimized designs reduce toxicity and unintended immune activation.
  • Strategies mitigate accelerated blood clearance, enabling repeated dosing.
  • Improved formulations enhance the therapeutic index of mRNA-LNPs.

Conclusions:

  • Therapeutic mRNA-LNPs necessitate unique design considerations separate from vaccines.
  • Lipid optimization and rational design are key to overcoming current limitations.
  • These advancements unlock the broader therapeutic potential of mRNA-LNP technology.